

PATENT Attorney Docket No.: RIB-005

(7995/7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Steitz et al.

SERIAL NO.:

10/072,634

GROUP NO.:

2683

FILING DATE:

February 8, 2002

EXAMINER:

Not yet assigned

TITLE:

Ribosome Structure and Protein Synthesis Inhibitors

RECEIVED

Commissioner for Patents Washington, D.C. 20231

APR 2 : ... =

Technology Center 2600

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the published patent documents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the published patent documents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND

Supplemental Information Disclosure Statement

Serial No.: 10/072,634

Page 2 of 2

the requisite Statement is below, **AND**the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement: or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: April 15, 2003 Reg. No.: 38,678

Tel. No.: (617) 248-7317 Fax No.: (617) 248-7100 WH Sper

Respectfully submitted.

Duncan A. Green Analgh Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110



FORM PTO - 1449

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: RIB-005

APPLICANTS: Steitz et al.

RECEIVED

SERIAL NO.: 10/072,634

APR 2

FILING DATE: February 8, 2002 Technology Center 2600

GROUP:

2683

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A4	US-2002-0086308 A1	07/04/02	Steitz et al.			08/03/01
	A5	5,693,791	12/02/97	Truett			04/11/95
	A 6	5,866,549	02/02/99	Or et al.	<u> </u>		07/03/97
	A7	5,336.768	08/09/94	Albrecht et al.			05/24/88
	Α8	5,281,703	01/25/94	White et al.			05/07/93
	Α9	5,180,719	01/19/93	White et al.			04/29/91
	A10	6,468,979 B1	10/22/02	Pellacini et al.			07/27/99
	A11	6,437,119 B1	08/20/02	Truett			07/17/00
	A12	5,905,144	05/18/99	Truett			09/15/97
	A13	5,466,681	11/14/95	Krivan et al.			01/12/94
	A14	6,380,356 B1	04/30/02	Griffin et al.			12/07/99
-	A15	6,446.032 B1	09/03/02	Schimmel			08/14/92

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	B4	EP 1 186 614 A2	03/13/02	EP			07/16/01		
	B5	EP I 188 769 A2	03/20/02	EP			08/09/01		
	В6	WO 00/32619	06/08/00	WO			11/24/99		
	В7	WO 95/07271	03/16/95	wo			08/16/94		
	В8	WO 96/18633	06/20/96	wo			12/07/95		
	B9	WO 97/35195	09/25/97	wo			03/19/97		

EXAMINER

DATE CONSIDERED





FORM PTO - 1449

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: RIB-005

APPLICANTS: Steitz et al.

SERIAL NO.: 10/072,634

RECEIVED 4PR 2 -

FILING DATE: February 8, 2002

Technology Center 2600

			OTHER ART, JOU	JRNAL ARTICL	E3, D1C.				
			CUMENTS: (Including Author, Title, I	Place of Publication,	Relevant Pages, D	pare)			
XAM. GT.	OTHER	CDO			LDMA	Complexed with an Aminoglycoside			
	C101 Fourmy et al. (1996) "Structure of the A Site of Escherichia coli 16S Ribosomal RNA Complexed with an Aminoglycosid								
	C101	An	ermann et al. (1999) "Docking of Cationic Antibiotics to Negatively Charged Pockets in RNA Folds" <u>J. Med. Chem.</u>						
	C102	He	rmann et al. (1999) "Docking of Cationic	Antibiotics to Negativ	vely Charged 1 ock				
	(102	42	42(7):1250-1261 Toannou et al. (1998) "Kinetics of Inhibition of Rabbit Reticulocyte Peptidyltransferase by Anisomycin and Sparsomycin" Toannou et al. (1998) "Kinetics of Inhibition of Rabbit Reticulocyte Peptidyltransferase by Anisomycin and Sparsomycin"						
	C103	lo	annou et al. (1998) "Kinetics of Inhibition	of Rabbit Reticulocy	te reputaymanisees				
	105	Molecular Pharmacology 53(6):1089-1096 Molecular Pharmacology 53(6):1089-1096							
	C104	Molecular Pharmacology 53(6):1089-1096 Kirillov et al. (1999) "Peptidyl Transferase Antibiotics Perturb the Relative Positioning of the 3'-Terminal Adenosine of P/P'-Site-Bound tRNA and 23S rRNA in the Ribosome" RNA 5(8):1003-1013							
		P	/P'-Site-Bound tRNA and 235 TKNA in all	at Dagading Cent	er of 16 S Ribosom	nal RNA" <u>J. Mol. Biol.</u> 273(3):586-599			
	C105	S	pickler et al. (1997) "Streptomycin Binds Wong et al. (1998) "Specificity of Aminog	to the Decoding Com	or the A-Site of the	Decoding Region of Ribosomal RNA"			
	C106	+,	Wong et al. (1998) "Specificity of Aminog	tycoside Antibiotics i	of the World				
		. I	or date: & Biology 5(7):397-400						
	C10	,	European Search Report for Application N	10. 02253442.2 dated	. Computer-Simulated New-Generation Inhibitor of Bacterial Ribosomal ty 106:6114-6115				
	C10	8	Hanessian et al. (1984) ""Quantamycin":	: A Computer-Simulat	ed New-Generalis				
			Hanessian et al. (1984) Quantanyem - Hanessian et al. (1984) Quantanyem - Guantanyem - Hanessian et al. (1984) Quantanyem						
 -	C10)9	Vince et al. (1975) "Chloramphenicol Bi	nding Site With Artano					
1			Agents and Chemotherapy 8(4), 437 713						
	C1	10	Shuker et al. (1996) "Discovering High-	Allunty Ligands	Activity Relationsh	nips to the Antibiotic A201A" Bioorganic			
	C110 Shuker et al. (1996) "Discovering High-Af C111 Hecker et al. (1993) "Application of Hygro			gromycin A Structure 98					
			Medicinal Chemistry Letters 3(2):295-2	acidas: Design Synt	nesis and RNA Bin	ding" <u>Bioorganic & Medicinal Chemistry</u>			
	C112 Wang et al. (1997) "Dimeric Aminoglycos			cosides. Design -,					
-			Letters 7(14):1951-1956 Holmes et al. (1993) "Novel Dimeric P	enicillin Derived Inhi	bitors of HIV-1 Pro	teinase: Interaction with the Catalytic			
	C113 Holmes et al. (1993) "Novel Dimeric Fern Aspartates" <u>Bioorganic & Medicinal Cher</u>			hemistry Letters 3(4):	503-508	DAL" LAW Che			
			Aspairance Programme Rinding of a L	Dimeric Derivative of	Vancomycin with	Dimeric L-Lys-D-Ala-D-Ala" <u>J. Am. Che</u> i			
	C114 Rao et al. (1997) "Tight Binding of a 8 miles." Soc. 119:10286-10290					Dang Dalugge Systems"			
L		Thrombin-Sensitive Peptide Linkers for Biological Signal-responsive							
	C115 Tanihara et al. (1996) Thicking Peptides 19(3):421-425								
1	1_			D.4.7	TE CONSIDEREI				

APR 1 8 2003 Application Serial Number 10/072,634 Filing Date February 8, 2002 d TRADE! First Named Inventor Steitz RECEIVE Group Art Unit 2683 TRANSMITTAL Examiner Name Not yet assigned 3PR 3 **FORM** Attorney Docket No. RIB-005 Technology Center 1600 Patent No. Not applicable Issue Date Not applicable ENCLOSURES (check all that apply) Fee Transmittal Form Copy of Notice to File Missing Notice of Appeal to Board Parts of Application (PTO-1553) of Patent Appeals and Interferences Check Attached Copy of Fee Formal Drawing(s) Appeal Brief (in triplicate) Transmittal Form Amendment/Response Request For Continued Status Inquiry Examination (RCE) ☐ Preliminary Transmittal ☐ After Final \boxtimes Return Receipt Postcard ☐ Affidavits/declaration(s) Associate Power of Attorney Letter to Official \boxtimes Certificate of First Class Mailing Draftsperson under 37 C.F.R. 1.8 including Drawings [Total Sheets ____] Terminal Disclaimer Certificate of Facsimile Transmission under 37 C.F.R. 1.8 **Executed Declaration and Power** Petition for Extension of Additional Enclosure(s) Time of Attorney for Utility or Design (please identify below) Patent Application \boxtimes Supplemental Information Small Entity Statement Disclosure Statement \boxtimes Form PTO-1449 Copies of IDS CD(s) for large table or computer Citations (A4-A15, program B4-B9 and C101-C115) Certified Copy of Priority Amendment After Allowance Document(s) Request for Certificate of Sequence Listing submission Correction Paper Copy/CD ☐ Certificate of Correction (in Computer Readable Copy duplicate) Statement verifying identity of above SIGNATURE BLOCK

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator

Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street

Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100

Date: April 15, 2003 Reg. No. 38,678

Tel. No.: (617) 248-7317 Fax No.: (617) 248-7100

Respectfully submitted,

Duncan A. Greenhalch Attorney for Applicants

Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street Boston, MA 02110



PATENT Attorney Docket No.: RIB-005 (7995/7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Steitz et al.

SERIAL NO.:

10/072,634

GROUP NO.:

2683

FILING DATE:

February 8, 2002

EXAMINER:

Not yet assigned

TITLE:

Ribosome Structure and Protein Synthesis Inhibitors

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, DC 20231 on this 15th day of April, 2003.

Nicole Deane

Commissioner for Patents Washington, D.C. 20231

RECEIVED

Sir:

APR 2 1 10

Technology Center 2600

Submitted herewith are:

- 1. Transmittal Form (1 pg.);
- 2. Supplemental Information Disclosure Statement (2 pgs.);
- 3. Form PTO-1449 (2 pgs.);
- 4. Copies of Documents Cited as A4-A15, B4-B9 and C101-C115; and
- 5. Return Receipt Postcard.